RC
ABOS icon

Rangeley Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Rangeley Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.6K Buy
+35,000
New +$89.3K 0.08% 123

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Rangeley Capital's ABOS Position: Q1 2026 in Review

Rangeley Capital opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 35,000 shares worth $82.6K. The stake represents 0.08% of the portfolio and ranks #123 among its holdings.

84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Rangeley Capital held 35,000 shares of Acumen Pharmaceuticals worth $82.6K as of Q1 2026.
  • Acumen Pharmaceuticals was a new Rangeley Capital position in Q1 2026.
  • Acumen Pharmaceuticals made up 0.08% of Rangeley Capital's portfolio in Q1 2026, its #123 holding.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.